Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022

Author's Avatar
Feb 28, 2022

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its fourth quarter and full-year 2021 financial results on Thursday, March 3, 2022.